In the primary analysis that includes data through week 24, the observed improvement in 6-min walking distance favoured rituximab-treated patients, but this difference did not reach statistical significance.
← all excerpts
Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension.
1
—
—